![](https://investorshub.advfn.com/uicon/267543.png?cb=1474471081)
Wednesday, May 27, 2020 11:47:08 AM
So, does anyone find it rather intriguing that the newest BOD selection, Horizon CEO Walbert also skippers a rare disease/rheumatic company? Lupus fits that portfolio perfectly. Also Horizon's newest FDA drug is a Thyroid Eye Medication that is absolutely killing it sales wise out of the gates. tripled the expectations for first quarter of its market life. One of the common medications needed to treat Thyroid Eye Disease happens to be Chronic Dry Eye treatments as patients typically have Bulging eye and blinking complications.
Now that Walbert can access AUPH file cabinets at what point does he click and say. Holy Crap this company with unencumbered assets and patent protections in Horizon's neck of the woods with a team that can already achieve sales ramps in rheumatic disease... Just gets me thinking about that
Recent AUPH News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:06:59 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/01/2024 10:07:59 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 10:03:38 AM
- Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results • Business Wire • 08/01/2024 10:00:00 AM
- Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024 • Business Wire • 07/19/2024 10:00:00 AM
- Aurinia to Participate in Upcoming Investor Healthcare Conferences • Business Wire • 07/02/2024 10:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 09:25:28 PM
- Aurinia Announces 2024 Annual General Meeting Results • Business Wire • 06/14/2024 04:16:00 PM
- Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024 • Business Wire • 06/05/2024 10:00:00 AM
- Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce • Business Wire • 06/04/2024 09:30:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/04/2024 09:25:39 PM
- Aurinia Provides Update on Proxy Statement • Business Wire • 06/03/2024 10:30:00 PM
- Aurinia Will Attend 2024 Jefferies Global Healthcare Conference • Business Wire • 05/30/2024 10:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:16:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:14:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:11:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:09:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:07:15 PM
- Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024 • Business Wire • 05/14/2024 10:00:00 AM
- Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024 • Business Wire • 05/09/2024 10:00:00 AM
- Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference • Business Wire • 05/07/2024 10:00:00 AM
- Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results • Business Wire • 05/02/2024 10:00:00 AM
- Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month • Business Wire • 05/01/2024 10:00:00 AM
- The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program • Business Wire • 04/30/2024 10:00:00 AM
- New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference • Business Wire • 04/16/2024 02:48:00 PM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM